Rheumatoid arthritis

The DSU has written reports for a number of NICE Technology Appraisals in the disease area rheumatoid arthritis (RA):

  • Rheumatoid arthritis – adlimumab, etanercept, infliximab, certolizumab pegol, golumumab, abatacept and tocilizumab [in progress, ID537]

  • TA247 Tocilizumab for the treatment of rheumatoid arthritis (rapid review of TA198) (February 2012)

  • TA198 Tocilizumab for the treatment of rheumatoid arthritis (August 2010) replaced by TA247

  • Rheumatoid arthritis – adlimumab, etanercept and infliximab (sequential use) (suspended)

  • TA130 Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (October 2007)

Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab, Abatacept and Tocilizumab

Tocilizumab (rapid review)

Tocilizumab

NICE appraisal

TA198 Tocilizumab for the treatment of rheumatoid arthritis (August 2010) replaced by TA247

DSU report

Tocilizumab for the treatment of rheumatoid arthritis (PDF, 697KB) (May 2010)

Adalimumab, Etanercept and Infliximab (sequential use)

Adalimumab, Etanercept and Infliximab